ValuEngine upgraded shares of Amgen Inc. (NASDAQ:AMGN) from a hold rating to a buy rating in a report issued on Thursday.
AMGN has been the topic of a number of other research reports. Robert W. Baird reissued a neutral rating and set a $165.00 target price on shares of Amgen in a research report on Friday, March 17th. Mizuho set a $195.00 target price on shares of Amgen and gave the company a buy rating in a research report on Thursday, March 16th. Deutsche Bank AG started coverage on shares of Amgen in a research report on Friday, June 23rd. They set a hold rating and a $172.00 target price on the stock. Cowen and Company reissued a buy rating and set a $209.00 target price on shares of Amgen in a research report on Friday, March 17th. Finally, Goldman Sachs Group, Inc. (The) cut their target price on shares of Amgen from $208.00 to $202.00 and set a conviction-buy rating on the stock in a research report on Monday, March 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $185.65.
Amgen (AMGN) opened at 173.32 on Thursday. The company’s 50 day moving average is $162.22 and its 200 day moving average is $162.64. Amgen has a 12 month low of $133.64 and a 12 month high of $184.21. The stock has a market cap of $127.46 billion, a PE ratio of 16.46 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.15. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.60 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.90 EPS. On average, analysts anticipate that Amgen will post $12.43 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Amgen Inc. (NASDAQ:AMGN) Stock Rating Upgraded by ValuEngine” was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/07/12/amgen-inc-nasdaqamgn-stock-rating-upgraded-by-valuengine.html.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Glenview Trust Co purchased a new position in Amgen during the fourth quarter valued at $882,000. FMR LLC raised its stake in shares of Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock valued at $5,963,875,000 after buying an additional 4,144,154 shares during the last quarter. Hunter Associates Investment Management LLC raised its stake in shares of Amgen by 2.4% in the fourth quarter. Hunter Associates Investment Management LLC now owns 61,803 shares of the medical research company’s stock valued at $9,036,000 after buying an additional 1,475 shares during the last quarter. CWA Asset Management Group LLC raised its stake in shares of Amgen by 91.7% in the fourth quarter. CWA Asset Management Group LLC now owns 8,501 shares of the medical research company’s stock valued at $1,243,000 after buying an additional 4,067 shares during the last quarter. Finally, Coho Partners Ltd. raised its stake in shares of Amgen by 2.2% in the fourth quarter. Coho Partners Ltd. now owns 789,328 shares of the medical research company’s stock valued at $115,408,000 after buying an additional 16,833 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.